Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

Home

/

SVRA

S

Savara Inc. (SVRA)

NMS – Цена в реальном времени. Валюта: USD

5.66

+0.10 (1.71%)

Рынок открыт: Aug 12, 2026, 3:14 PM EDT

5.66

+0.09 (1.62%)

Предыдущая сессия: Aug 11, 2026, 7:47 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update. “While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term opportunity,” said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara. “Our focus is on the potential l.

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA's clinical and regulatory milestones as key investment drivers. Upcoming APAP BLA PDUFA is highlighted as a pivotal near-term catalyst.

Видео

No Data

There is no data to display

Пресс-релизы

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update. “While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term opportunity,” said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara. “Our focus is on the potential l.